News
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan
Waters to Acquire Andrew Alliance
Waters Corporation (NYSE:WAT) announced today that it has entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019. Novocure plans to discuss these
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today provided preliminary operational and financial results for the fourth quarter
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
Premier Inc. to Report Fiscal 2020 Second-Quarter Results and Host Conference Call Before Market Opens on February 4
Premier Inc. (NASDAQ: PINC) plans to report fiscal 2020 second-quarter financial results the morning of Feb. 4, 2020, followed by a conference call at 8 a.m. ET to discuss the results.
Conference
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!
Zu einem regelrechten Kursfeuerwerk kam es gestern bei der Aktie von Applied Genetic Technologies (WKN: A110V2), der Kurs konnte sich gestern von 4,16 auf 9,27 USD mehr als verdoppeln.
Grund für
Quidel Announces Preliminary Revenue for Fourth Quarter 2019
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Morphosys: Beste Perspektiven
Der Morphosys-Konzern (WKN: 663200) meldete sich zuletzt mit wichtigen medizinischen Updates, die es aufgrund ihrer Signifikanz zu beleuchten gilt.
Der Initiation der Phase 1-Studie von Tafasitamab
Morphosys: Beste Perspektiven
Der Morphosys-Konzern (WKN: 663200) meldete sich zuletzt mit wichtigen medizinischen Updates, die es aufgrund ihrer Signifikanz zu beleuchten gilt.
Der Initiation der Phase 1-Studie von Tafasitamab
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform
Evotec: Es regnet Millionen dank Bayer – wieder mal!
Vor zwei Tagen machte Evotec (WKN: 566480) die Erweiterung seiner iPSC-Allianz mit Bristol-Myers Squibb öffentlich (wir berichteten). Heute meldet der Hamburger Biotechkonzern eine „neue